{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:40:44Z","timestamp":1792032044206,"version":"4.4.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Purpose:<\/jats:title>\n                    <jats:p>Approximately 30% of ischemic strokes occur after a previous stroke or transient ischemic attack. Arterial hypertension is one of the best established risk factors for first and recurrent stroke, both ischemic and hemorrhagic. Guidelines for the secondary prevention of ischemic stroke support the use of blood pressure (BP)\u2013lowering drugs in most patients. However, the evidence for these recommendations comes from meta-analyses that included both ischemic and hemorrhagic stroke patients, whereas these 2 conditions differ quantitatively in several aspects. With this systematic review and meta-analysis, we aimed at summarizing the current evidence on BP-lowering drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials up to January 31, 2020. We included randomized controlled trials comparing any specific BP-lowering drug, as monotherapy or combination, with either a control or another BP-lowering drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eight studies that enrolled 33\u2009774 patients with ischemic stroke or transient ischemic attack were included in the meta-analysis. Mean follow-up was 25 months (range, 3\u201348). Moderate-quality evidence indicated that a subsequent stroke occurred in 7.9% (ischemic in 7.4% or hemorrhagic in 0.6%) of patients taking any type of BP-lowering drug compared with 9.7% of patients taking placebo (odds ratio, 0.79 [95% CI, 0.66\u20130.94]; absolute risk difference, \u22121.9% [95% CI, \u22123.1% to \u22120.5%]). Moderate-quality evidence indicated that mortality occurred similarly in patients taking any type of BP-lowering treatment compared with placebo, with an absolute risk of 7.3% and 7.9%, respectively (odds ratio, 1.01 [95% CI, 0.92\u20131.10]; absolute risk difference, 0.1% [95% CI, \u22120.6% to 0.7%]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The use of BP-lowering drugs in patients with ischemic stroke or transient ischemic attack is associated with a 1.9% risk reduction of stroke but does not affect the all-cause mortality risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/strokeaha.120.031945","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T05:01:46Z","timestamp":1619499706000},"page":"1974-1982","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Antihypertensive Drugs for Secondary Prevention After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis"],"prefix":"10.1161","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2551-525X","authenticated-orcid":true,"given":"Giorgio B.","family":"Boncoraglio","sequence":"first","affiliation":[{"name":"Departments of Cerebrovascular Disease (G.B.B.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[{"name":"Institute of Primary Health Care (BIHAM), University of Bern, Switzerland (C.D.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tramacere","sequence":"additional","affiliation":[{"name":"Research and Clinical Development (I.T.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68770-9"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000441139.02102.80"},{"key":"e_1_3_6_4_2","unstructured":"World Health Organization. The top 10 causes of death. Publication date: May 24 2018. Accessed March 18 2020. http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000152985.32732.EE"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000024"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.003666"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000092488.40085.15"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2009.139"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003302"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08485"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007858.pub2"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.006"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_3_6_15_2","unstructured":"Boncoraglio G Cinquini M Moschetti I Del Giovane C Tramacere I. Antihypertensive therapy for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. PROSPERO. 2018;CRD42018100148. http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42018100148"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"e_1_3_6_17_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins JPT","year":"2011","unstructured":"Higgins, JPT, Green, S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. www.handbook.cochrane.org"},{"key":"e_1_3_6_18_2","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013","author":"Sch\u00fcnemann H","year":"2013","unstructured":"Sch\u00fcnemann, H, Bro\u017cek, J, Guyatt, G, Oxman, A (eds). GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working Group; 2013. www.guidelinedevelopment.org\/handbook"},{"key":"e_1_3_6_19_2","volume-title":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]","author":"Evidence Prime Inc","year":"2015","unstructured":"Evidence Prime Inc. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, Canada; 2015. gradepro.org"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1974.03230420021019"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000107813"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.1967"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200305000-00011"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000166048.35740.a9"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000194120.42722.ac"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(70)91577-1"},{"key":"e_1_3_6_29_2","first-page":"344","article-title":"Nicardipine in the prevention of cerebral infarction.","volume":"12","author":"Mart\u00ed Mass\u00f3 JF","year":"1990","unstructured":"Mart\u00ed Mass\u00f3, JF, Lozano, R. Nicardipine in the prevention of cerebral infarction. Clin Ther. 1990;12:344\u2013351.","journal-title":"Clin Ther"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.19.4.512"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.24.4.543"},{"key":"e_1_3_6_32_2","first-page":"710","article-title":"Post-stroke antihypertensive treatment study. A preliminary result.","volume":"108","author":"PATS Collaborating Group","year":"1995","unstructured":"PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl). 1995;108:710\u2013717.","journal-title":"Chin Med J (Engl)"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000106480.76217.6F"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000221212.36860.c9"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804593"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70198-4"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000100105"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60104-9"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.008512"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12446"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.540781"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60516-3"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1107281"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000211"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.021254"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000069"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2167"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01225-8"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.120.031945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:20:08Z","timestamp":1770384008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.120.031945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1161\/STROKEAHA.120.031945"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.120.031945","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2020-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}